Karyopharm Therapeutics Target of Unusually Large Options Trading (NASDAQ:KPTI)

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of some unusual options trading on Thursday. Stock investors purchased 10,965 call options on the stock. This represents an increase of 817% compared to the typical daily volume of 1,196 call options.

Karyopharm Therapeutics Trading Down 6.6%

Shares of KPTI stock traded down $0.67 during trading hours on Thursday, hitting $9.42. 317,017 shares of the company were exchanged, compared to its average volume of 572,696. The company has a market capitalization of $172.76 million, a PE ratio of -0.57 and a beta of 0.21. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $10.99. The business has a 50 day moving average of $7.48 and a two-hundred day moving average of $6.56.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. On average, research analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. raised its stake in Karyopharm Therapeutics by 112.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after acquiring an additional 790,417 shares during the period. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics in the 4th quarter valued at $74,000. Ikarian Capital LLC lifted its holdings in shares of Karyopharm Therapeutics by 1,897.9% during the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after buying an additional 517,297 shares in the last quarter. Tudor Investment Corp ET AL acquired a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at about $95,000. Finally, Quadrature Capital Ltd bought a new position in Karyopharm Therapeutics during the fourth quarter worth about $439,000. Institutional investors own 66.44% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on KPTI. Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, February 18th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $14.83.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.